HUNgarian COronaVirus Disease-19 Epidemiological Research

June 11, 2020 updated by: Semmelweis University Heart and Vascular Center

Hungarian CoronaVirus Disease-19 Epidemiological Research

Hungarian CoronaVirus disease-19 Epidemiological Research

Study Overview

Status

Unknown

Conditions

Detailed Description

The planned large-scale, cross-sectional, representative population screening can show the prevalence of COVID-19 and the degree of infection and trans-infection in Hungary after more than one month of strict restriction. In addition, it can have an impact on further actions, and we can track the impact of the decisions we make by repeating the screenings.

Study Type

Observational

Enrollment (Anticipated)

11200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hungary
      • Budapest, Hungary, 1122
      • Debrecen, Hungary, 4032
      • Pecs, Hungary, 7622
      • Szeged, Hungary, 6720
        • Recruiting
        • University of Szeged
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Hungarian male or female patients aged 14 and over who live in private households.

Description

Inclusion Criteria:

  • Hungarian male or female patients aged 14 and over who live in private households
  • Inactivated social security number does not infer the exclusion of the study

Exclusion Criteria:

  • Patients under the age of 14
  • Patients living in institutional households

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
COVID-19 rate
Time Frame: 1 year
The rate of the infected patients, asymptomatic carrier and healed patients
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Semmelweis University Heart and Vascular Center

Collaborators

University of Pecs
Semmelweis University
Szeged University
University of Debrecen

Investigators

  • Principal Investigator: Béla Merkely, PhD,DSc, Semmelweis University Heart and Vascular Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 1, 2020

Primary Completion (ANTICIPATED)

May 1, 2021

Study Completion (ANTICIPATED)

August 1, 2021

Study Registration Dates

First Submitted

April 28, 2020

First Submitted That Met QC Criteria

April 28, 2020

First Posted (ACTUAL)

April 30, 2020

Study Record Updates

Last Update Posted (ACTUAL)

June 16, 2020

Last Update Submitted That Met QC Criteria

June 11, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H-UNCOVER

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronavirus Infection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe